EGFR and coronary atherosclerosis: As a highly selective inhibitor of SGLT-2, CANA reduces endothelial injury to slow coronary atherosclerosis by reducing ROS production and blocking oxidative stress signaling pathway (EGFR/Src/Rho-kinase) mediated by ROS [22].